Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

BACKGROUND: PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide–targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with chronic migr...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen, Diamond, Merle, Hindiyeh, Nada A., Biondi, David M., Cady, Roger, Hirman, Joe, Allan, Brent, Pederson, Susan, Schaeffler, Barbara, Smith, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539382/
https://www.ncbi.nlm.nih.gov/pubmed/33023473
http://dx.doi.org/10.1186/s10194-020-01186-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539382/
https://www.ncbi.nlm.nih.gov/pubmed/33023473
http://dx.doi.org/10.1186/s10194-020-01186-3

Ejemplares similares